Abstract
Endothelin (ET) was discovered in 1988 and is the most potent vasoconstrictive peptide known to date. It exists in three isoforms (ET-1 to ET-3) and acts on two endothelin receptor subtypes, the endothelin-A (ETA)-receptor and the endothelin-B (ETB)-receptor. Endothelin receptor antagonists are novel therapeutics in clinical development for different cardiovascular, cerebrovascular, and renal diseases. Several different structural classes of endothelin receptor antagonists have been discovered within the last decade, starting from peptidic- and peptidomimetic structures to small organic molecules suitable as therapeutics for oral administration. Focussing on the small organic molecules, the different structural classes of ET-receptor antagonists are described with respect to synthesis, structure-activity-relationships, receptor-subtype-selectivity profile, and where possible, intended therapeutic indications.
Keywords: Endothelin Receptor Antagonists, Sitaxsentan, Darusentan, Tezosentan, Myriceric Acid-Derivatives, Pyrrolidine-3-Carboxylic Acids, Tetra-Substituted Pyrimidine
Current Medicinal Chemistry
Title: Endothelin Receptor Antagonists: Structures, Synthesis, Selectivity and Therapeutic Applications
Volume: 9 Issue: 3
Author(s): C. Boss, M. Bolli and T. Weller
Affiliation:
Keywords: Endothelin Receptor Antagonists, Sitaxsentan, Darusentan, Tezosentan, Myriceric Acid-Derivatives, Pyrrolidine-3-Carboxylic Acids, Tetra-Substituted Pyrimidine
Abstract: Endothelin (ET) was discovered in 1988 and is the most potent vasoconstrictive peptide known to date. It exists in three isoforms (ET-1 to ET-3) and acts on two endothelin receptor subtypes, the endothelin-A (ETA)-receptor and the endothelin-B (ETB)-receptor. Endothelin receptor antagonists are novel therapeutics in clinical development for different cardiovascular, cerebrovascular, and renal diseases. Several different structural classes of endothelin receptor antagonists have been discovered within the last decade, starting from peptidic- and peptidomimetic structures to small organic molecules suitable as therapeutics for oral administration. Focussing on the small organic molecules, the different structural classes of ET-receptor antagonists are described with respect to synthesis, structure-activity-relationships, receptor-subtype-selectivity profile, and where possible, intended therapeutic indications.
Export Options
About this article
Cite this article as:
Boss C., Bolli M. and Weller T., Endothelin Receptor Antagonists: Structures, Synthesis, Selectivity and Therapeutic Applications, Current Medicinal Chemistry 2002; 9 (3) . https://dx.doi.org/10.2174/0929867023371139
DOI https://dx.doi.org/10.2174/0929867023371139 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Benefits of Resistance Training in Older Adults
Current Aging Science Hypovitaminosis D is Associated with Endothelial Dysfunction in Patients with Metabolic Syndrome
Current Vascular Pharmacology Combined Angiogenic and Osteogenic Factor Delivery for Bone Regenerative Engineering
Current Pharmaceutical Design Normal Bicaudate Index by Aging
Current Medical Imaging T Cell Response in Rheumatic Fever: Crossreactivity Between Streptococcal M Protein Peptides and Heart Tissue Proteins
Current Protein & Peptide Science Pexelizumab and its Role in the Treatment of Myocardial Infarction and in Coronary Artery Bypass Graft Surgery: A Review
Recent Patents on Cardiovascular Drug Discovery Similarities and Differences Between Carotid Artery and Coronary Artery Function
Current Cardiology Reviews Inflammasomes in the Pathophysiology of Maternal Obesity: Potential Therapeutic Targets to Reduce Long-Term Adverse Health Outcomes in the Mother and Offspring
Current Vascular Pharmacology Statins and Carotid Intima-Media Thickness Reduction: An Up-to-Date Review
Current Medicinal Chemistry Elevated Aβ42 in Aged, Non-demented Individuals with Cerebral Atherosclerosis
Current Alzheimer Research Proteome Adjustments Post Gradual Hypoxic Stress in Barilius bendelisis: Insights into Adaptive Strategies of a Hill Stream Cyprinid
Current Proteomics Intracerebral Hemorrhage and Diabetes Mellitus: Blood-Brain Barrier Disruption, Pathophysiology and Cognitive Impairments
CNS & Neurological Disorders - Drug Targets Comparison Between the Effects of Bupivacaine and Levobupivacaine for Spinal Anesthesia on QT Dispersion
Cardiovascular & Hematological Disorders-Drug Targets The Role of Diabetes Mellitus in Diseases of the Gallbladder and Biliary Tract
Current Diabetes Reviews Bioactive Molecules from the <i>Alpinia</i> Genus: A Comprehensive Review
Current Pharmaceutical Biotechnology The Vasopressin V1b Receptor as a Therapeutic Target in Stress-related Disorders
Current Drug Targets - CNS & Neurological Disorders Antioxidant, Xanthine Oxidase and Monoamine Oxidase Inhibitory Potential of Coumarins: A Review
Current Organic Chemistry Current Therapeutic Strategies and Future Perspectives for the Treatment of Venous Thromboembolism
Current Pharmaceutical Design Repetitive Transient Phosphodiesterase-3 Inhibition Eliminates Non-ischemic Cardiac Remodeling and Failure
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Recent Advancement and Technological Aspects of Pulsatile Drug Delivery System - A Laconic Review
Current Drug Targets